[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan.
One case of generalized myalgia caused by oxaliplatin
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
|
[3] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[4] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[5] |
FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe.
Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
|
[6] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[7] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[8] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|
[9] |
HE Huizhen, GUO Yixian, SUN Wanling.
Research progress on targeting CD47 in treatment of lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1071-1077.
|
[10] |
HUANG Jinjian, ZHANG Xiaomeng, ZHANG Bing, DING Xueli, YANG Ying, LIN Zhijian.
Cardiovascular risk signaling mining and mechanism of uric acid-lowering drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 866-871.
|
[11] |
ZAN Ke, ZHAO Lei, JIANG Dacheng, WANG Ying, JIN Hongyu, MA Yu, MA Shuangcheng.
Determination of 135 pesticide residues in Farfarae Flos by UPLC-MS/MS and risk assessment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 885-890.
|
[12] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[13] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[14] |
MENG Kangkang, LIU Saiyue.
After-marketing safety of coenzyme Q10 for injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 795-798.
|
[15] |
HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong.
Automatic monitoring and assessment of antibiotics-related thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
|